Business Context and Reporting Period
This Form 8-K was filed by Signal Genetics, Inc. on November 28, 2016. The report addresses regulatory compliance status and updates regarding a proposed merger with Miragen Therapeutics, Inc.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only quantitative metric disclosed is the stock price performance required for regulatory compliance: the closing bid price of the Company's common stock was at or above $1.00 per share for at least ten consecutive trading days as of November 21, 2016.
Material Changes
- NASDAQ Compliance: The Company received notification from NASDAQ that it has regained compliance with Marketplace Rule 5550(a)(2). This resolves a noncompliance notice originally dated November 24, 2015.
- Merger Status: The Company reaffirmed its intent to proceed with a proposed merger with Miragen Therapeutics, Inc., with plans to file a registration statement on Form S-4 containing a proxy statement/prospectus.
Outlook, Risks, and Management Commentary
Management urges investors to read the upcoming Form S-4 and related proxy materials before making voting or investment decisions regarding the proposed merger. The filing includes standard legal disclaimers stating that this communication does not constitute an offer to sell or a solicitation of an offer to buy securities. No specific risks or contingencies beyond the standard merger process were detailed in this specific report.
Investor Verification Checklist
- Verify the upcoming filing of the Form S-4 registration statement for the Signal Genetics and Miragen Therapeutics merger.
- Confirm the continued maintenance of the $1.00 minimum bid price to sustain NASDAQ compliance.
- Review the full text of the press release attached as Exhibit 99.1 for additional details on the compliance resolution.